SC144 is primarily investigated for its potential as an anticancer agent. It functions as a small molecule inhibitor that targets the gp130 receptor, which is part of the IL-6 signaling pathway. This pathway is often overactive in various cancers, contributing to tumor growth, survival, and resistance to therapy. By inhibiting gp130, SC144 helps suppress downstream signaling cascades such as JAK/STAT and MAPK, leading to reduced cancer cell proliferation and increased apoptosis. It has shown promising activity in preclinical studies against ovarian, breast, and prostate cancers, particularly in cell lines that exhibit resistance to conventional chemotherapy. SC144 also demonstrates the ability to overcome drug resistance by modulating survival pathways and enhancing the sensitivity of cancer cells to other treatments. Due to its mechanism of action and selectivity, SC144 is considered a candidate for targeted cancer therapy, especially in tumors driven by inflammatory signaling. Research is ongoing to evaluate its efficacy in combination with other anticancer drugs and its potential for in vivo applications.